Source comparison
PT-141 Dosage Timing: Clinical vs Experimental Comparison
FDA-Approved (Vyleesi) 1.75mg subcutaneous Minimum 45 minutes 60–90 minutes post-injection 90–180 minutes post-injection Designed for predictable timing in clinical populations. Conservative window accounts for individual absorption variability Research Protoc
This comparison does not assign a generated winner or score.
- FDA-Approved (Vyleesi)
- 1.75mg subcutaneous
- Minimum 45 minutes
- 60–90 minutes post-injection
- 90–180 minutes post-injection
- Designed for predictable timing in clinical populations. Conservative window accounts for individual absorption variability
- Research Protocol (low-dose titration)
- 0.5–1.0mg subcutaneous
- 50–60 minutes
- 70–100 minutes post-injection
- 100–200 minutes post-injection
- Lower doses may extend time-to-peak slightly due to reduced concentration gradient. Timing window shifts 10–20 minutes later
- Research Protocol (high-dose)
- 2.0mg subcutaneous
- 40–50 minutes
- 55–85 minutes post-injection
- 80–160 minutes post-injection
- Higher doses accelerate receptor saturation. Earlier injection timing compensates for faster onset
- Self-Administered (experimental)
- 1.5–2.0mg subcutaneous
- 45–60 minutes
- Matches FDA timing but often uses compounded peptide without batch-level potency verification. Timing consistency depends on peptide purity
- The table shows that pt-141 sexual health protocol dosage timing adjusts slightly across dose ranges, but the core principle remains: inject during the window that aligns peak plasma concentration with the start of desired arousal. Not hours before, not minutes before.